Clinical Trials on Hepatic Encephalopathy in United Kingdom

Total 1112 results

Shire

Completed

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

Healthy | Hepatic Impairment

United States
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
PPD Development, L.P.

Recruiting

DZD9008 PK Study in Hepatic Impairment Subjects

Hepatic Impairment

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
AstraZeneca
Parexel

Terminated

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Hepatic Impairment

United States
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
University of California, San Francisco
Boston University; Johns Hopkins University; Children's Hospital of Philadelphia and other collaborators

Completed

High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL)

Neonatal Encephalopathy | Birth Asphyxia

United States
Amgen

Completed

Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

Hepatic Impairment

United States
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Hepatic Impairment

United States
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Terminated

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Pfizer

Completed

A Hepatic Impairment Study for PF-04965842.

Hepatic Impairment

United States
Imperial College London

Unknown

Analysis of Human Knee Joint Fluid Using Metabonomic, Genomic and Tribology Techniques

Osteoarthritis | Rheumatoid Arthritis | Septic Arthritis

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Healthy | Hepatic Impairment

United States
AstraZeneca

Recruiting

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Hepatic Impairment

United States
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Shionogi

Completed

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Hepatic Impairment

United States
AbbVie

Terminated

A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Daiichi Sankyo, Inc.

Completed

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

Hepatic Impairment

United States
Sanofi

Completed

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

Hepatic Impairment

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Recruiting

MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

Liver Failure | Acute-On-Chronic Liver Failure | Liver Disease | Cirrhosis of the Liver

Switzerland, United Kingdom
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

Germany, United States, Hungary
Akebia Therapeutics

Completed

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Zogenix, Inc.
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Active, not recruiting

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Dravet Syndrome | Epileptic Encephalopathy | Lennox Gastaut Syndrome

United States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Mexico, Netherlands, Poland, Spain, Sweden, United Kingdom
AstraZeneca

Recruiting

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Hepatic Impairment

United States
Array Biopharma, now a wholly owned subsidiary...

Terminated

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function (MEK162)

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Pfizer

Completed

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

Healthy | Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction

United States
Insmed Incorporated

Completed

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Hepatic Impairment

United States
Galectin Therapeutics Inc.

Completed

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Eli Lilly and Company
AstraZeneca

Withdrawn

A Study of LY3314814 in Participants With Liver Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

Hepatic Impairment

United States
FUJIFILM Toyama Chemical Co., Ltd.
Celerion

Completed

PK Study of T-817 in Subjects With Hepatic Impairment

Healthy | Hepatic Impairment

United States
MDVI, LLC

Completed

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

Healthy | Hepatic Impairment

United States
Amgen

Completed

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

Hepatic Impairment | Solid Tumors | Hematologic Malignancies

United Kingdom, Netherlands, United States, France
Novartis Pharmaceuticals

Completed

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Hepatic Impairment

United States
University of Texas Southwestern Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Study of N-Acetylcysteine in Acute Liver Failure (ALF) (ONAC)

Acute Liver Failure | Fulminant Hepatic Failure

United States
Lateral Pharma Pty Ltd

Completed

Oral LAT8881 in Neuropathic Pain

Neuropathic Pain | Diabetic Peripheral Neuropathy (DPN) | Post Herpetic Neuralgia (PHN)

Australia, United Kingdom
University of South Florida
University of Miami; University of Alabama at Birmingham; Icahn School of Medicine... and other collaborators

Completed

Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria

Porphyrias

United States
The Cleveland Clinic

Active, not recruiting

SVC and Its Relationship to CVP Measurements in Liver Transplantation

Liver Failure

United States
SecuraBio

Completed

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects (IPI-145-14)

Hepatic Impairment

United States
Virginia Commonwealth University

Withdrawn

Hepatocyte Transplantation in Liver Failure

Liver Failure

United States
Kadmon, a Sanofi Company

Completed

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States

3

Subscribe